SFM
ARCT icon

Sphera Funds Management’s Arcturus Therapeutics ARCT Stock Holding History

Sphera Funds Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-8,014
Closed -$866K – 130
2014
Q3 		$866K Buy
+8,014
New +$1.04M 0.11% 112

Other funds holding ARCT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Sphera Funds Management's ARCT Position: Q2 2015 in Review

Sphera Funds Management sold out of Arcturus Therapeutics (ARCT) in Q2 2015, closing a stake of 29 shares — an estimated $1K sold.

Sphera Funds Management first reported a position in ARCT in Q4 2014 and held it in 2 quarters. The position peaked at $144K in Q4 2014. 32 funds tracked by Wall St. Rank hold ARCT as of Q2 2015.

  • Sphera Funds Management reported no remaining Arcturus Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Sphera Funds Management sold 29 Arcturus Therapeutics shares in Q2 2015, an estimated $1K.
  • Sphera Funds Management first reported a position in Arcturus Therapeutics in Q4 2014 and held it in 2 quarters.
  • Sphera Funds Management's Arcturus Therapeutics position peaked at $144K in Q4 2014.
  • 32 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2015.

Based on Sphera Funds Management's 13F filing for Q2 2015, filed 6 Aug 2015.